D Proietti
Overview
Explore the profile of D Proietti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tontini M, Romano M, Proietti D, Balducci E, Micoli F, Balocchi C, et al.
Vaccine
. 2017 Apr;
35(19):2612.
PMID: 28365250
No abstract available.
2.
Tontini M, Romano M, Proietti D, Balducci E, Micoli F, Balocchi C, et al.
Vaccine
. 2016 Jun;
34(35):4235-4242.
PMID: 27317455
Glycoconjugate vaccines are made of carbohydrate antigens covalently bound to a carrier protein to enhance their immunogenicity. Among the different carrier proteins tested in preclinical and clinical studies, five have...
3.
Pecetta S, Tontini M, Faenzi E, Cioncada R, Proietti D, Seubert A, et al.
Vaccine
. 2016 Mar;
34(20):2334-41.
PMID: 27015733
Glycoconjugate vaccines are composed of capsular polysaccharides (CPSs) of a pathogenic bacteria covalently linked to carrier proteins. Pre-exposure to the carrier is known to influence the efficacy of the glycoconjugate,...
4.
Pecetta S, Vijayakrishnan B, Romano M, Proietti D, Lo Surdo P, Balocchi C, et al.
Vaccine
. 2016 Feb;
34(11):1405-11.
PMID: 26845738
Diphtheria toxin mutant CRM197 is a common carrier protein for glycoconjugate vaccines, which has been proven an effective protein vector for, among others, meningococcal carbohydrates. The wide-range use of this...
5.
Pecetta S, Lo Surdo P, Tontini M, Proietti D, Zambonelli C, Bottomley M, et al.
Vaccine
. 2014 Dec;
33(2):314-20.
PMID: 25448110
Glycoconjugate vaccines play an enormous role in preventing infectious diseases. The main carrier proteins used in commercial conjugate vaccines are the non-toxic mutant of diphtheria toxin (CRM197), diphtheria toxoid (DT)...
6.
Tontini M, Berti F, Romano M, Proietti D, Zambonelli C, Bottomley M, et al.
Vaccine
. 2013 Aug;
31(42):4827-33.
PMID: 23965218
Glycoconjugate vaccines are among the most effective and safest vaccines ever developed. Diphtheria toxoid (DT), tetanus toxoid (TT) and CRM197 have been mostly used as protein carriers in licensed vaccines....
7.
Micoli F, Adamo R, Proietti D, Gavini M, Romano M, MacLennan C, et al.
Anal Biochem
. 2013 Aug;
442(2):259-61.
PMID: 23938776
A method for meningococcal X (MenX) polysaccharide quantification by high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) is described. The polysaccharide is hydrolyzed by strong acidic treatment, and the peak...
8.
Berti F, Romano M, Micoli F, Pinto V, Cappelletti E, Gavini M, et al.
Vaccine
. 2012 Aug;
30(45):6409-15.
PMID: 22921741
Prior to the introduction of the MenAfriVac™ serogroup A glycoconjugate vaccine in September 2010, serogroup A was the major epidemic disease-causing meningococcal serogroup in the African meningitis belt. However, recently...
9.
Micoli F, Rondini S, Pisoni I, Proietti D, Berti F, Costantino P, et al.
Vaccine
. 2010 Dec;
29(4):712-20.
PMID: 21115057
An efficacious, low cost vaccine against typhoid fever, especially for young children, would make a major impact on disease burden in developing countries. The virulence capsular polysaccharide of Salmonella Typhi...
10.
Ravenscroft N, DAscenzi S, Proietti D, Norelli F, Costantino P
Dev Biol (Basel)
. 2001 Feb;
103:35-47.
PMID: 11214252
Glycoconjugate vaccines are being developed against Haemophilus influenzae (Hib) and meningococcal Type A and C micro-organisms; they consist of oligosaccharides of intermediate chain length conjugated to the carrier protein CRM...